Targeting intrinsic apoptosis and other forms of cell death by BH3-mimetics in glioblastoma

BH3-mimetics and BET-inhibitors elicit enhanced lethality in malignant glioma

(2017) Chiaki Tsuge Ishida et al.   Oncotarget

Mitochondrial matrix chaperone and c-myc inhibition causes enhanced lethality in glioblastoma

(2017) Chiaki Tsuge Ishida et al.   Oncotarget

A Synthetic Cell-Penetrating Dominant-Negative ATF5 Peptide Exerts Anticancer Activity against a Broad Spectrum of Treatment-Resistant Cancers

(2016) G. Karpel-Massler et al.   CLINICAL CANCER RESEARCH

OTX015 (MK-8628), a novel BET inhibitor, displaysin vitroandin vivoantitumor effects alone and in combination with conventional therapies in glioblastoma models

(2016) Caroline Berenguer-Daizé et al.   INTERNATIONAL JOURNAL OF CANCER

BET Bromodomain Inhibitors Enhance Efficacy and Disrupt Resistance to AR Antagonists in the Treatment of Prostate Cancer

(2016) I. A. Asangani et al.   MOLECULAR CANCER RESEARCH

Interference with the HSF1/HSP70/BAG3 Pathway Primes Glioma Cells to Matrix Detachment and BH3 Mimetic–Induced Apoptosis

(2016) Patrick Antonietti et al.   MOLECULAR CANCER THERAPEUTICS

Venetoclax Approved for CLL

(2016)   Cancer Discovery

Blastic Plasmacytoid Dendritic Cell Neoplasm Is Dependent on BCL2 and Sensitive to Venetoclax

(2016) Joan Montero et al.   Cancer Discovery

Metabolic reprogramming of glioblastoma cells by L-asparaginase sensitizes for apoptosis in vitro and in vivo

(2016) Georg Karpel-Massler et al.   Oncotarget

Inhibition of deubiquitinases primes glioblastoma cells to apoptosis in vitro and in vivo

(2016) Georg Karpel-Massler et al.   Oncotarget

Bromodomain inhibitor OTX015 in patients with lymphoma or multiple myeloma: a dose-escalation, open-label, pharmacokinetic, phase 1 study

(2016) Sandy Amorim et al.   Lancet Haematology

Targeting MYCN-Driven Transcription By BET-Bromodomain Inhibition

(2015) A. Henssen et al.   CLINICAL CANCER RESEARCH

Bcl2L12 with a BH3-like domain in regulating apoptosis and TMZ-induced autophagy: A prospective combination of ABT-737 and TMZ for treating glioma

(2015) MING-CHANG YANG et al.   INTERNATIONAL JOURNAL OF ONCOLOGY

Toward precision medicine in glioblastoma: the promise and the challenges

(2015) Michael D. Prados et al.   NEURO-ONCOLOGY

Assessment of ABT-263 activity across a cancer cell line collection leads to a potent combination therapy for small-cell lung cancer

(2015) Anthony C. Faber et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Potent and selective small-molecule MCL-1 inhibitors demonstrate on-target cancer cell killing activity as single agents and in combination with ABT-263 (navitoclax)

(2015) J D Leverson et al.   Cell Death & Disease

Combined inhibition of Bcl-2/Bcl-xL and Usp9X/Bag3 overcomes apoptotic resistance in glioblastoma in vitro and in vivo

(2015) Georg Karpel-Massler et al.   Oncotarget

TIC10/ONC201 synergizes with Bcl-2/Bcl-xL inhibition in glioblastoma by suppression of Mcl-1 and its binding partners in vitro and in vivo

(2015) Georg Karpel-Massler et al.   Oncotarget

Sorafenib Sensitizes Glioma Cells to the BH3 Mimetic ABT-737 by Targeting MCL1 in a STAT3-Dependent Manner

(2015) Irina Kiprianova et al.   NEOPLASIA

PI3K and Bcl-2 Inhibition Primes Glioblastoma Cells to Apoptosis through Downregulation of Mcl-1 and Phospho-BAD

(2014) Fresia Pareja et al.   MOLECULAR CANCER RESEARCH

Usp9x- and Noxa-mediated Mcl-1 downregulation contributes to pemetrexed-induced apoptosis in human non-small-cell lung cancer cells

(2014) J Yan et al.   Cell Death & Disease

Obatoclax (GX15-070) triggers necroptosis by promoting the assembly of the necrosome on autophagosomal membranes

(2013) F Basit et al.   CELL DEATH AND DIFFERENTIATION

YM-155 Potentiates the Effect of ABT-737 in Malignant Human Glioma Cells via Survivin and Mcl-1 Downregulation in an EGFR-Dependent Context

(2013) E. P. Jane et al.   MOLECULAR CANCER THERAPEUTICS

Structure-guided design of a selective BCL-XL inhibitor

(2013) Guillaume Lessene et al.   Nature Chemical Biology

ABT-199, a potent and selective BCL-2 inhibitor, achieves antitumor activity while sparing platelets

(2013) Andrew J Souers et al.   NATURE MEDICINE

OBATOCLAX and ABT-737 Induce ER Stress Responses in Human Melanoma Cells that Limit Induction of Apoptosis

(2013) David Wroblewski et al.   PLoS One

Dual Inactivation of Akt and ERK by TIC10 Signals Foxo3a Nuclear Translocation, TRAIL Gene Induction, and Potent Antitumor Effects

(2013) J. E. Allen et al.   Science Translational Medicine

p53-dependent regulation of Mcl-1 contributes to synergistic cell death by ionizing radiation and the Bcl-2/Bcl-XL inhibitor ABT-737

(2011) Katrin E. Tagscherer et al.   APOPTOSIS

BET Bromodomain Inhibition as a Therapeutic Strategy to Target c-Myc

(2011) Jake E. Delmore et al.   CELL

HSP70 Protein Promotes Survival of C6 and U87 Glioma Cells by Inhibition of ATF5 Degradation

(2011) Guangfu Li et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

Multiple BH3 Mimetics Antagonize Antiapoptotic MCL1 Protein by Inducing the Endoplasmic Reticulum Stress Response and Up-regulating BH3-only Protein NOXA

(2011) Tina C. Albershardt et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

RNAi screen identifies Brd4 as a therapeutic target in acute myeloid leukaemia

(2011) Johannes Zuber et al.   NATURE

The GCN2-ATF4 pathway is critical for tumour cell survival and proliferation in response to nutrient deprivation

(2010) Jiangbin Ye et al.   EMBO JOURNAL

The Pan-Bcl-2 Inhibitor (-)-Gossypol Triggers Autophagic Cell Death in Malignant Glioma

(2010) V. Voss et al.   MOLECULAR CANCER RESEARCH

Selective inhibition of BET bromodomains

(2010) Panagis Filippakopoulos et al.   NATURE

A genome-wide RNA interference screen reveals an essential CREB3L2-ATF5-MCL1 survival pathway in malignant glioma with therapeutic implications

(2010) Zhi Sheng et al.   NATURE MEDICINE

Obatoclax induces Atg7-dependent autophagy independent of beclin-1 and BAX/BAK

(2010) F McCoy et al.   Cell Death & Disease

Deubiquitinase USP9X stabilizes MCL1 and promotes tumour cell survival

(2009) Martin Schwickart et al.   NATURE

IDH1andIDH2Mutations in Gliomas

(2009) Hai Yan et al.   NEW ENGLAND JOURNAL OF MEDICINE

ABT-263: A Potent and Orally Bioavailable Bcl-2 Family Inhibitor

(2008) C. Tse et al.   CANCER RESEARCH

Discovery of ABT-263, a Bcl-family protein inhibitor: observations on targeting a large protein–protein interaction

(2008) Michael D Wendt   Expert Opinion on Drug Discovery

Apoptosis-based treatment of glioblastomas with ABT-737, a novel small molecule inhibitor of Bcl-2 family proteins

(2008) K E Tagscherer et al.   ONCOGENE

An Integrated Genomic Analysis of Human Glioblastoma Multiforme

(2008) D. W. Parsons et al.   SCIENCE